

Bloomberg Global Innovative Biopharma Index Methodology

March 2024

Bloomberg

Contents

Introduction	3
Section 1: Overview	3
Section 2: Bloomberg Intelligence	3
Section 3: Index Eligibility Process	3
Parent Universe	3
Sector Eligibility	3
Liquidity Eligibility	3
Market Capitalization Eligibility	3
Thematic Eligibility	3
Multiple Classes of Securities	3
Section 4: Index Construction Process	4
Index Selection Process	4
Index Weighting	4
Index Rebalance and Reconstitution	4
Section 5: Index Maintenance	5
Index Calculation	5
Deletion Policy	5
Addition Policy	5
Replacement Policy	5
Corporate Actions	5
Appendix I: Risks and Limitations of the Indices	6
Risks	6
Limitations of the index	6
Appendix II: Benchmark Oversight and Governance	6
Benchmark governance, audit and review structure	6
Index and data reviews	6
Expert judgement	6
Conflicts of interest	6
Restatement policy	7
Cessation Policy	7
Appendix III: ESG Disclosure	8

Introduction

The Bloomberg Global Innovative Biopharma Index is constructed to track the performance of innovative biotech companies measured by drug licensing activities and large pharmaceutical companies.

Section 1: Overview

Name	Bloomberg Global Innovative Biopharma Index
Base date	2015-03-30
Inception Date	2024-03-11
Reconstitution	Semiannual
Share Rebalance	Quarterly
Publication	Weekdays
Currency	USD
Tickers	BGIBP (Price Return) BGIBT (Total Return) BGIBN (Net Return)

Section 2: Bloomberg Intelligence

Bloomberg Intelligence (BI), with in-depth data and analysis from 400+ research professionals on 2,000+ companies, 135+ industries and 21 markets, helps clients make more informed decisions in rapidly changing markets. BI analysts and strategists identify long term growth trends, and through independent research, identify and categorize the companies exposed to a theme. The BI Drug licensing data provides statistics of drug licensing deals, such as average upfront, average deal value with company/drug-level details. Includes historical data from the past 10 years to help users better evaluate licensing fees. Bloomberg Index Services Limited ("BISL") utilizes the BI Drug licensing data to determine index eligibility.

Section 3: Index Eligibility Process

Parent Universe

To be selected for the Bloomberg Global Innovative Biopharma Index, a security must be a member of the Bloomberg World Large, Mid & Small Cap Index. Please refer to the Bloomberg Global Equity Index methodology through the link below for additional details.

[Bloomberg Global Equity Index Methodology](#)

Sector Eligibility

Security must belong to Large Pharma (sector code 16101010) or Biotech (sector code 16101011) as defined by Bloomberg Industry Classification System (BICS).

Liquidity Eligibility

A security must have a minimum 90-day average daily value traded of \$5 million.

Market Capitalization Eligibility

A security must have a minimum free float market capitalization of \$200 million.

Thematic Eligibility

A security must have drug licensing deals at phase of Pre-Clinical/ Discovery, Phase I, Phase II or Phase III for the previous 24 months as of the Selection Date to be eligible for the Index.

Multiple Classes of Securities

One security per issuer is permitted. If an issuer has multiple securities, then the security currently in the Index will take precedence if it has met all other criteria for eligibility. Otherwise, the security with the highest 90-day average daily value traded is eligible for inclusion in the Index.

Section 4: Index Construction Process

Index Selection Process

Step 1. Calculate the rolling 24-month drug licensing activity score (“DLAS”)

The rolling 24-month DLAS is computed for issuers within Biotech that satisfy the Index Eligibility Process in Section 2. Each of the eligible phases is assigned a Phase Score. DLAS for each issuer is determined by calculating the sum of the Phase Score of all the eligible phases.

Eligible Phase	Phase Score
Phase III	1
Phase II	0.5
Phase I	0.25
Pre-Clinical/ Discovery	0.1

Step 2. Rank the issuers by DLAS in descending order and select the top 20 companies for index inclusion. In the event that there is a tie, the issuer with the higher Issuer Free Float Market Capitalization¹ will take priority in the ranking.

Step 3. Select the top 10 issuers within Large Pharma that satisfy the Index Eligibility Process in Section 2 based on the Issuer Free Float Market Capitalization for index inclusion.

Index Weighting

The Index is modified market cap weighted. 70% of index weight is assigned to issuers within Biotech, the remaining 30% of index weight is assigned to issuers within Large Pharma. Securities are free float market capitalization weighted and capped at 4.5%. Any excess weight from capping is distributed proportionally to all the remaining uncapped securities within the group.

Index Rebalance and Reconstitution

The Index is reconstituted semiannually in March and September. It is also rebalanced for share changes quarterly in March, June, September, and December.

Selection Date

The Index Eligibility Process and Index Selection Process are applied using data as of the last Wednesday in January and July.

Index Share Determination Date

Index are determined using prices, float shares as of the second to last Wednesday in February, May, August, and November.

Index Announcement Date

An Index reconstitution and rebalance for share changes are announced on the last Wednesday in February, May, August, and November.

Index Effective Date

The Index reconstitutions and rebalances go effective after the close of trading on the second Wednesday in March, June, September, and December.

		Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
Selection Date (Eligibility)	Last Wednesday	X						X					
Share Determination Date (Weighting)	Second to Last Wednesday		X			X			X			X	
Announcement Date	Last Wednesday		X			X			X			X	
Effective Date	Second Wednesday			X			X			X			X

¹ Issuer free float market capitalization is calculated as the sum of free float market capitalization of all securities, under the same company, that satisfy the Index Eligibility Process in Section 3.

Section 5: Index Maintenance

Index Calculation

Refer to the [Bloomberg Global Equity Indices Methodology](#) for index calculation details.

Deletion Policy

Index securities are not deleted outside of the Index Rebalance and Reconstitution window except in the case of a delisting.

Addition Policy

Index securities are not added outside of the Index Reconstitution.

Replacement Policy

Index securities are not replaced outside of the Index Reconstitution.

Corporate Actions

Refer to [Bloomberg Global Equity Indices Non-Market Cap Corporate Action Methodology](#) for the treatment of corporate actions.

Appendix I: Risks and Limitations of the Indices

Risks

The following is a summary of certain risks associated with the Index but is not meant to be an exhaustive list of all risks associated with the Index. Although the Index is designed to be representative of the markets it is measuring, it may not be representative of every use case. There is also inherent, though transparent, judgment in its construction, as outlined in this Methodology. The Index is designed for general applicability and not to address the individual circumstances and needs of users. BISL does not advise about the usefulness of the Index to a particular circumstance; users are therefore encouraged to seek their own counsel for such matters. This Methodology is subject to change, which may impact its usefulness to users. Although efforts will be made to alert users of any change, every individual user may not be aware of them. Such changes may also significantly impact the usefulness of the Index. BISL may also decide to cease publication of this Index. BISL maintains internal policies regarding user transitions, but no guarantee is given that an adequate alternative is available generally or for a particular use case. Markets for stocks, as with all markets, can be volatile. As the Index is designed to measure this market, it could be materially impacted by market movements, thus significantly affecting the use or usefulness of the Index for some or all users. Also, certain equity markets are less liquid than others – even the most liquid markets may suffer periods of illiquidity. Illiquidity can have an impact on the quality or amount of data available to BISL for calculation and may cause the Index to produce unpredictable results.

Limitations of the index

Though the Index is designed to be representative of the markets it measures or otherwise aligns with its stated objective, it may not be representative in every case or achieve its stated objective in all instances. It is designed and calculated strictly to follow the rules of this Methodology, and any Index level or other output is limited in its usefulness to such design and calculation.

Markets can be volatile, including those market interests that the Index measures or upon which the Index is dependent to achieve its stated objective. For example, illiquidity can have an impact on the quality or amount of data available to the administrator for calculation and may cause the Index to produce unpredictable or unanticipated results.

In addition, market trends and changes to market structure may render the objective of the Index unachievable or to become impractical to replicate by investors.

In particular, the Index measures global equity markets. As with all equity investing, the Index is exposed to market risk. The value of equities fluctuate with the changes in economic forecasts, interest rate policies established by central banks and perceived geopolitical risk. The Index does not take into account the cost of replication and as a result a tracking portfolio's returns will underperform the Index with all else equal. As the Index is designed to measure those markets, it could be materially impacted by market movements, thus significantly impacting the use or usefulness of the fixings for some or all users.

In addition, certain sub-indices may be designed to measure smaller subsets of the Index such as specific styles, size, and sector. Some of these sub-indices have very few qualifying constituents and may have none for a period of time. During such period, the sub-index will continue to be published at its last value, effectively reporting a 0% return, until new constituents qualify. If no constituents are expected to qualify (due to changes in market structure and other factors), the sub-index may be discontinued. In such an event, this discontinuation will be announced to index users.

Appendix II: Benchmark Oversight and Governance

Benchmark governance, audit and review structure

Please refer to the BISL Benchmark Procedures Handbook available [here](#).

Index and data reviews

Please refer to the BISL Benchmark Procedures Handbook available [here](#).

Expert judgement

Please refer to the BISL Benchmark Procedures Handbook available [here](#).

Conflicts of interest

Please refer to the BISL Benchmark Procedures Handbook available [here](#).

Restatement policy

Please refer to the BISL Benchmark Procedures Handbook available [here](#).

Cessation Policy

Please refer to the BISL Benchmark Procedures Handbook available [here](#).

Appendix III: ESG Disclosure

EXPLANATION OF HOW ESG FACTORS ARE REFLECTED IN THE KEY ELEMENTS OF THE BENCHMARK METHODOLOGY	
Item 1. Name of the benchmark administrator.	Bloomberg Index Services Limited ("BISL")
Item 2. Type of benchmark or family of benchmarks. Choose the relevant underlying asset from the list provided in Annex II to Commission Delegated Regulation (EU)2020/1816.	Equity
Item 3. Name of the benchmark or family of benchmarks.	Bloomberg Global Innovative Biopharma Index
Item 4. Does the benchmark methodology for the benchmark or family of benchmarks take into account ESG factors?	No
<p>Item 5. Where the response to Item 4 is positive, please list below, for each family of benchmarks, those ESG factors that are taken into account in the benchmark methodology, taking into account the ESG factors listed in Annex II to Delegated Regulation (EU) 2020/1816.</p> <p>Please explain how those ESG factors are used for the selection, weighting or exclusion of underlying assets. The ESG factors shall be disclosed at an aggregated weighted average value at the level of the family of benchmarks.</p>	
a) List of environmental factors considered:	Not applicable
b) List of social factors considered:	Not applicable
c) List of governance factors considered:	Not applicable
<p>Item 6. Where the response to Item 4 is positive, please list below, for each benchmark, those ESG factors that are taken into account in the benchmark methodology, taking into account the ESG factors listed in Annex II to Delegated Regulation (EU) 2020/1816, depending on the relevant underlying asset concerned.</p> <p>Please explain how those ESG factors are used for the selection, weighting or exclusion of underlying assets. The ESG factors shall not be disclosed for each constituent of the benchmark, but shall be disclosed at an aggregated weighted average value of the benchmark.</p> <p>Alternatively, all of this information may be provided in the form of a hyperlink to a website of the benchmark administrator included in this explanation. The information on the website shall be easily available and accessible. Benchmark administrators shall ensure that information published on their website remains available for five years.</p>	
a) List of environmental factors considered:	As above
b) List of social factors considered:	As above
c) List of governance factors considered:	As above
Item 7. Data and standards used	
a) Data input. <i>(i) Describe whether the data are reported, modelled or, sourced internally or externally.</i> <i>(ii) Where the data are reported, modelled or sourced externally, please name the third party data provider.</i>	Not Applicable
b) Verification and quality of data. <i>Describe how data are verified and how the quality of those data is ensured.</i>	Not Applicable
c) Reference standards <i>Describe the international standards used in the benchmark methodology.</i>	Not Applicable
Date on which information has been last updated and reason for the update:	March 2024

Disclaimer

BLOOMBERG, BLOOMBERG INDICES and the Bloomberg Global Innovative Biopharma Index (the "Index") are trademarks or service marks of Bloomberg Finance L.P. Bloomberg Finance L.P. and its affiliates, including Bloomberg Index Services Limited, the administrator of the Indices (collectively, "Bloomberg") or Bloomberg's licensors own all proprietary rights in the Indices. Bloomberg does not guarantee the timeliness, accuracy or completeness of any data or information relating to the Indices. Bloomberg makes no warranty, express or implied, as to the Indices or any data or values relating thereto or results to be obtained therefrom, and expressly disclaims all warranties of merchantability and fitness for a particular purpose with respect thereto. It is not possible to invest directly in an Index. Back-tested performance is not actual performance. Past performance is not an indication of future results. To the maximum extent allowed by law, Bloomberg, its licensors, and its and their respective employees, contractors, agents, suppliers and vendors shall have no liability or responsibility whatsoever for any injury or damages - whether direct, indirect, consequential, incidental, punitive or otherwise - arising in connection with the Indices or any data or values relating thereto - whether arising from their negligence or otherwise. This document constitutes the provision of factual information, rather than financial product advice. Nothing in the Indices shall constitute or be construed as an offering of financial instruments or as investment advice or investment recommendations (i.e., recommendations as to whether or not to "buy", "sell", "hold", or to enter or not to enter into any other transaction involving any specific interest or interests) by Bloomberg or a recommendation as to an investment or other strategy by Bloomberg. Data and other information available via the Indices should not be considered as information sufficient upon which to base an investment decision. All information provided by the Indices is impersonal and not tailored to the needs of any person, entity or group of persons. Bloomberg does not express an opinion on the future or expected value of any security or other interest and do not explicitly or implicitly recommend or suggest an investment strategy of any kind. Customers should consider obtaining independent advice before making any financial decisions. © 2024 Bloomberg. All rights reserved. This document and its contents may not be forwarded or redistributed without the prior consent of Bloomberg.

The BLOOMBERG TERMINAL service and Bloomberg data products (the "Services") are owned and distributed by Bloomberg Finance L.P. ("BFLP") except (i) in Argentina, Australia and certain jurisdictions in the Pacific islands, Bermuda, China, India, Japan, Korea and New Zealand, where Bloomberg L.P. and its subsidiaries distribute these products, and (ii) in Singapore and the jurisdictions serviced by Bloomberg's Singapore office, where a subsidiary of BFLP distributes these products.

Take the next step.

For additional information,
email indexhelp@bloomberg.net
or press the <HELP> key twice
on the Bloomberg Terminal*

[bloomberg.com/indices](https://www.bloomberg.com/indices)

Beijing

+86 10 6649 7500

Dubai

+971 4 364 1000

Frankfurt

+49 69 9204 1210

Hong Kong

+852 2977 6000

London

+44 20 7330 7500

Mumbai

+91 22 6120 3600

New York

+1 212 318 2000

San Francisco

+1 415 912 2960

São Paulo

+55 11 2395 9000

Singapore

+65 6212 1000

Sydney

+61 2 9777 8600

Tokyo

+81 3 4565 8900